A method for co-cultivation and directed differentiation induction of muscle satellite cells and adipose-derived stem cells is provided. The method includes the steps of co-cultivation and co-differentiation. The method for co-cultivation and directed differentiation induction of muscle satellite cells and adipose-derived stem cells provided by the present disclosure can allow the effective co-cultivation and co-directed differentiation induction of muscle satellite cells and adipose-derived stem cells from Larimichthys crocea, thereby providing a feasible solution for the large-scale production of high-quality cultivated meat.

Human progenitor T cells that are able to successfully engraft a murine thymus and differentiate into mature human T and NK cells are described. The human progenitor T cells have the phenotype CD34+CD7+CD 1aCD5 or CD34+CD7+CD1aCD5+ and are derived from human hematopoietic stem cells, embryonic stem cells and induced pluripotent stem cells by coculture with cells expressing a Notch receptor ligand (OP9-DL1 or OP9-DL4). Such cells are useful in a variety of applications including immune reconstitution, the treatment of immunodeficiencies and as carriers for genes used in gene therapy.

Methods of differentiating a mesenchymal stromal cell (MSC) to a first non-MSC cell fate, the method comprising contacting the MSC with extracellular vesicles (EVs), matrix-bound vesicles (MBVs) or a combination thereof are provided. Methods of producing artificial tissue by culturing MSCs with two sets of vesicles each comprising EVs, MBVs or both that differentiate MSCs to two different non-MSC cell fates, methods of culturing with reduced growth factors and method of differentiating an MSC to a muscle cell fate are also provided.

Disclosed are methods of assessing the ability of a candidate therapeutic agent to reverse, reduce or prevent intestinal injury by a potential toxic agent using a three-dimensional, engineered, bioprinted, biological intestinal tissue model. Also disclosed are methods of assessing the effect of an agent on intestinal function, the method comprising contacting the agent with a three-dimensional, engineered, bioprinted, biological intestinal tissue model.

Disclosed are methods of assessing the ability of a candidate therapeutic agent to reverse, reduce or prevent intestinal injury by a potential toxic agent using a three-dimensional, engineered, bioprinted, biological intestinal tissue model. Also disclosed are methods of assessing the effect of an agent on intestinal function, the method comprising contacting the agent with a three-dimensional, engineered, bioprinted, biological intestinal tissue model.

The method involves producing a hybrid cultured meat product by decellularizing plant scaffolds through sequential exposure to decellularizing agents and rinsing to achieve a low residual DNA level. The decellularized plant scaffolds are seeded with mammalian or poultry cells or cells derived therefrom. The seeded decellularized plant scaffolds and then mixed with a protein source and a binding agent to form a mixture, which is shaped into the desired form. The process may include specific treatments with sodium dodecyl sulfate and bleach, and the use of a protein source and transglutaminase as components. The resulting product offers unique textures and nutritional values from the combination of plant scaffolds and protein sources.